Promosome LLC and Lonza Biologics Announce Evaluation Contract for Promosome's Translation...

* Reuters is not responsible for the content in this press release.

Mon May 18, 2009 8:00am EDT

Promosome LLC and Lonza Biologics Announce Evaluation Contract for Promosome's
Translation Enhancing Elements (TEEs)

NEW YORK, May 18, 2009 (GLOBE NEWSWIRE) -- Promosome LLC, a biotechnology
company specializing in technologies related to the regulation of protein
synthesis through translation initiation, today announced the signing of a
non-exclusive technology evaluation contract with Lonza Biologics. Lonza is a
recognized leader providing a large repertoire of contract manufacturing and
enabling technologies to the pharmaceutical and biopharmaceutical industry.

Under the terms of the agreement, Lonza will evaluate Promosome's Translation
Enhancing Elements (TEEs) in combination with its proprietary GS(tm) expression
technology. Promosome's TEEs are synthetic messenger RNA (mRNA) sequences that
can be used to greatly enhance protein expression in a variety of eukaryotic
cells. TEEs are expected to be highly complementary to Lonza's proprietary
GS(tm) expression technology.

"The opportunity to collaborate with Lonza, an organization recognized to be at
the forefront of the biopharmaceutical manufacturing field, further demonstrates
the growing level of interest in the commercial potential of our translation
enhancing technology," said John Manzello, Promosome's President and Chief
Executive Officer.

About Promosome

Promosome is a New York City based biotechnology company founded by the highly
regarded Life Sciences commercialization team of William J. Gedale and John R.
Costantino. The mission of Promosome is to leverage and commercialize the
discoveries of Nobel Laureate Dr. Gerald M. Edelman, Dr. Vincent P. Mauro and
their colleagues at The Scripps Research Institute (TSRI) in La Jolla,
California while in parallel, offering a significant return to investors and
contributing to the advancement of the biotechnology industry. Promosome has
established a Research Funding and Option Agreement with TSRI and the
laboratories of Doctors Edelman and Mauro. Promosome has world-wide exclusive
license and sub-license rights to the TEE Technology.

For more information on Promosome and its TEE technology, please visit
www.promosome.com.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare
and life science industries. Its products and services span its customers' needs
from research to final product manufacture. Lonza is the global leader in the
production and support of active pharmaceutical ingredients both chemically as
well as biotechnologically. Biopharmaceuticals are one of the key growth drivers
of the pharmaceutical and biotechnology industries. Lonza has strong
capabilities in large and small molecules, peptides, amino acids and niche
bioproducts which play an important role in the development of novel medicines
and healthcare products. Lonza is a leader in cell-based research, endotoxin
detection and cell therapy manufacturing. Lonza is headquartered in Basel,
Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of
CHF 2.87 billion. Further information can be found at www.lonza.com.

-0-
CONTACT:  Promosome LLC 
          John F. Manzello
          +1-508-845-2255
          jmanzello@promosome.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.